Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry
Edward R. Kastenhuber, Javier A. Jaimes, Jared L. Johnson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 15

Showing 15 citing articles:

ACE2-Independent Interaction of SARS-CoV-2 Spike Protein with Human Epithelial Cells Is Inhibited by Unfractionated Heparin
Lynda J. Partridge, Lucy Urwin, Martin J. H. Nicklin, et al.
Cells (2021) Vol. 10, Iss. 6, pp. 1419-1419
Open Access | Times Cited: 63
COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
Daniele Focosi, Massimo Franchini, Liise‐anne Pirofski, et al.
Viruses (2021) Vol. 13, Iss. 8, pp. 1594-1594
Open Access | Times Cited: 40
Accelerating discovery: A novel flow cytometric method for detecting fibrin(ogen) amyloid microclots using long COVID as a model
Simone Turner, Gert Jacobus Laubscher, Asad Khan, et al.
Heliyon (2023) Vol. 9, Iss. 9, pp. e19605-e19605
Open Access | Times Cited: 13
Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants
Bin Tu, Huiyuan Wang, Xinran An, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 7, pp. 3187-3194
Open Access | Times Cited: 17
COVID‐19 coagulopathies: Human blood proteins mimic SARS‐CoV‐2 virus, vaccine proteins and bacterial co‐infections inducing autoimmunity
Robert Root‐Bernstein
BioEssays (2021) Vol. 43, Iss. 12
Open Access | Times Cited: 21
Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties
Tim Hempel, Katarina Elez, Nadine Krüger, et al.
Chemical Science (2021) Vol. 12, Iss. 38, pp. 12600-12609
Open Access | Times Cited: 19
Hindrance of the Proteolytic Activity of Neutrophil-Derived Serine Proteases by Serine Protease Inhibitors as a Management of Cardiovascular Diseases and Chronic Inflammation
Timo Burster, Zhadyra Mustafa, Dinara Myrzakhmetova, et al.
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 17
Intermediate- vs. Standard-Dose Prophylactic Anticoagulation in Patients With COVID-19 Admitted in Medical Ward: A Propensity Score-Matched Cohort Study
David M. Smadja, Guillaume Bonnet, Nicolas Gendron, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 15
Anti-prothrombin autoantibodies enriched after infection with SARS-CoV-2 and influenced by strength of antibody response against SARS-CoV-2 proteins
Marc Emmenegger, Sreedhar Saseendran Kumar, Vishalini Emmenegger, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 10
Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19
Jonathan H. Shrimp, John Janiszewski, Catherine Z. Chen, et al.
ACS Infectious Diseases (2022) Vol. 8, Iss. 6, pp. 1191-1203
Open Access | Times Cited: 7
The Fight against COVID-19 on the Multi-Protease Front and Surroundings: Could an Early Therapeutic Approach with Repositioning Drugs Prevent the Disease Severity?
Annamaria Vianello, Serena Del Turco, Serena Babboni, et al.
Biomedicines (2021) Vol. 9, Iss. 7, pp. 710-710
Open Access | Times Cited: 9
Optimization of anticoagulant therapy in elderly patients after viral infection COVID-19
L. O. Vidzizheva, А. Р. Умерова, А. В. Коханов, et al.
ASTRAKHAN MEDICAL JOURNAL (2024) Vol. 19, Iss. 4, pp. 6-15
Closed Access
Proteolysis and deficiency of α1-proteinase inhibitor in SARS-CoV-2 infection
О. Е. Акбашева, Л. В. Спирина, D. A. Dyakov, et al.
Biomeditsinskaya Khimiya (2022) Vol. 68, Iss. 3, pp. 157-176
Closed Access | Times Cited: 2
A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19
Jonathan H. Shrimp, John Janiszewski, Catherine Z. Chen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Proteolysis and Deficiency of α1-Proteinase Inhibitor in SARS-CoV-2 Infection
О. Е. Акбашева, Л. В. Спирина, D. A. Dyakov, et al.
Biochemistry (Moscow) Supplement Series B Biomedical Chemistry (2022) Vol. 16, Iss. 4, pp. 271-291
Open Access | Times Cited: 1
Page 1

Scroll to top